So technically every stock I buy has greater
dividends than the commission.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger
than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay
dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange
Commission (the SEC).
Spending on
commissions by its $ 21 billion Equity
Dividend Fund increased by 39 percent from the 2014 to 2016 fiscal years, but the fund's transaction activity more
than doubled, meaning that its
commission rate overall decreased considerably.
Historically, for shareholders participating in the DRIP, American Stock Transfer & Trust Company, LLC (the «Plan Agent») used cash
dividends to purchase shares of NHF in the secondary market when the price of NHF's shares, plus estimated brokerage
commissions, was less
than NAV, or distributed newly issued common shares when the price of NHF's shares, plus estimated brokerage
commissions, was equal to or greater
than NAV.
To be more specific, the
dividend amount paid must be equal or more
than the cost of the
commission fee paid to acquire the shares.
After
commission this brought in $ 21.01 or $ 0.21 a share — more
than two
dividend payments!
It came to the same conclusion with regard to Germany taxing
dividends to foreign shareholders heavier
than domestic in Case C - 284 / 09
Commission / Germany and Finland taxing
dividends distributed to foreign pension in a discriminatory manner in Case C - 342 / 10
Commission / Finland.